Emerging technology and future developments in flow cytometry

Hematology/Oncology Clinics of North America

Volumn 16, Issue 2, 2002, Pages 477-495

  Stewart, Carleton C ^a   Goolsby, Charles ^b   Shackney, Stanley E ^c,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUOROCHROME; IMATINIB; MONOCLONAL ANTIBODY CD3; OKT 3; FLUORESCENT DYE; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ANALYTIC METHOD; FLOW CYTOMETRY; IMMUNOASSAY; INSTRUMENTATION; PRIORITY JOURNAL; REVIEW; ROBOTICS; SUSPENSION ARRAY TECHNOLOGY; TECHNOLOGY; CELL COUNT; FORECASTING; IMMUNOLOGY; METHODOLOGY; NEOPLASM; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; SUSPENSION;

ANTIBODIES, MONOCLONAL; CELL COUNT; FLOW CYTOMETRY; FLUORESCENT DYES; FORECASTING; NEOPLASM PROTEINS; NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; ROBOTICS; SUSPENSIONS;

EID: 0036086542     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00013-2     Document Type: Review

References (66)

1. High speed automatic blood cell counter and cell size analyzer
2. Electronic separation of biological cells by volume
3. Spectrophotometer: New instrument for ultra rapid cell analysis
4. Rapid biological cell identification by spectroscopic analysis
5. Instrumentation for automated examination of cellular specimens
6. Cell sorting: Automated separation of mammalian cells as a function of intracellular fluorescence
7. Fluorescence activated cell sorting
8. An historical review of the development of flow cytometers and sorters
9. Rapid multiple mass constituent analysis of biological cells
10. Impulsfluorometrie-ein neuartiges durchflussverfahren zur ultraschnellen mengenbestimmung von zellinhaltsstoffen
11. Automated analysis of deoxyribonucleic acid, protein and nuclear to cytoplasmic relationships in tumor cells and gynecologic specimen
12. New preparing and staining procedures for specific and rapid analysis of DNA distributions
13. Natural T cells. Cells that co-express NKRP-1 and TCR
14. Characterization of NKT cells in human peripheral blood and decidual lymphocytes
15. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation
16. Highly efficient infrared-to-visible energy upconversion in Er+3; Y203
17. Two-photon photodynamic therapy
18. Radiation detection performance of very high gain avalanche photodiodes
19. Flow cytometric monitoring of HIV-infected patients: Simultaneous enumeration of five lymphocyte subsets
20. The hybridizationstabilization assay: A solution-based isothermal method for rapid screening and determination of sequence preference of ligands that bind to duplexed nucleic acids
21. Kinetics of antibody binding to cells
22. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay
23. True multiplexed analysis by computer-enhanced flow cytometry
24. Advanced multiplexed analysis with the flowmetrix system
25. Classification and properties of 64 multiplexed microsphere sets
26. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres
27. Flow cytometry-based minisequencing: A new platform for high-throughput single-nucleotide polymorphism scoring
28. Multiparameter analysis of human epithelial tumor cell lines by laser scanning cytometry
29. The erbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
30. The erbB-2/Her2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
31. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
32. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
33. erbB-2 and erbB-3 is potently induced by neu differentiation facor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 amplification
34. Expression of c-erbB-3 protein in primary breast carcinomas
35. Epidermal growth factor receptor, c-erbB2, and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells
36. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade
37. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups
38. Common patterns of genetic evolution in human solid tumors
39. Genetic alterations in primary bladder cancers and their metastases
40. Genetic instability in colorectal cancers
41. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 amplification by fluorescence in situ hybridization in primary human breast cancers
42. The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: Clinical prognostic implications
43. ras in human breast cancers: Evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients
44. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas
45. OKT3 prophylaxis in kidney transplant recipients: Drug monitoring by flow cytometry
46. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization
47. OKT3-treated kidney transplant patients: Monitoring of effects on peripheral blood mononuclear cells by using two-color flow cytometry
48. A flow cytometric method for the detection of the development of antibody to Orthoclone OKT3
49. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients
50. Lymphoid aggregates in bone marrow masquerading as residual lymphoma following Ritusam (rituximab) therapy for non-Hodgkin's lymphoma
51. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
52. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20
53. The biology and treatment of chronic myelogenous leukemia
54. Targeted therapies for the myeloid leukaemias
55. Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia
56. The bcr-ab1 gene in chronic myelogenous leukaemia
57. Malignant transformation by ab1 and bcr/ab1
58. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
59. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors